Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Pfizer

The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's NVO Wegovy.

3 Stocks to Focus on as Demand for Obesity Drugs Booms

Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet demand, a top company official told Reuters.

Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats

Amgen

The companies that already have obesity drugs can't keep up with the demand for their treatments, and the demand for the drugs is only likely to become more intense. That's because over 42% of the U.S. population was obese as of 2020, while the pervasive publicity around these drugs will make them more popular, and the social and political pressure for insurers to cover the treatments will become more intense.

3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals

Novo Nordisk has the income flow to pay a dividend for the long term. It also has a pipeline full of candidates to keep the growth going.

Is Novo Nordisk a Good Passive Income Stock?

Ozempic, Wegovy and other diabetes/weight loss drugs were prescribed more than 9 million times in the US during the fourth quarter of 2022, according to a new report.  A Trilliant Health analysis of insurance claims from about 300 million Americans found that prescriptions for the drugs quadrupled from early 2020 to the end of 2022.

US prescriptions for Ozempic and other weight loss drugs surged to 9 million in 4Q 2022

Novo Nordisk (NYSE:NVO)'s stellar growth is unlikely to slow this year, according to Stifel, which was updating its views after a call with the Danish pharma's management. “Our main takeaway is that we should not expect any inflexion in the strong growth momentum that it had year-to-date,” said the broker.

Novo Nordisk Wegovy surge to continue, says Stifel

The data confirms the rise in demand for GLP-1s, which have fueled a frenzy among Americans and on Wall Street for their ability to cause weight loss.

Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years

High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospects.

2 Magnificent Dividend Stocks to Buy Right Now

Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.

Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs

Novo Nordisk's shares are undervalued, with the company's intrinsic value estimated to be at least double its current value. The success of Novo Nordisk's weight loss medication, Wegovy, has led to increased demand and plans to increase production capacity. The healthcare sector, including Novo Nordisk, is historically cheap compared to the broader market, presenting a buying opportunity.

Novo Nordisk: DCF Analysis Suggests Significant Undervaluation

Denmark's Novo Nordisk (NVO) struck a deal with U.S.-based health tech firm Valo Health to use artificial intelligence (AI) to discover and develop treatments for cardiometabolic diseases such as heart attack, stroke, and diabetes.

Novo Nordisk and Valo Health to Use AI to Develop Treatments for Cardiometabolic Diseases

AstraZeneca

Novartis

Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over the long-term, we expect investors to reward earnings upgrade stories - Novo Nordisk, Novartis, AstraZeneca - in the near-term,” it said.

Morgan Stanley sees biopharma sector as a 'safe haven'

Novo Nordisk (NYSE:NVO) has announced a collaboration with Valo Health to discover and develop novel treatments for cardiometabolic using Valo's artificial intelligence (AI)-powered Opal Computational Platform. Under the agreement, the two organizations will leverage Opal for access to real-world patient data, AI-enabled small molecule discovery and Biowire human tissue modelling platform designed to speed up the discovery and development process.

Novo Nordisk announces AI collaboration with Valo Health for cardiometabolic treatments

Danish drugmaker Novo Nordisk said on Monday it would collaborate with U.S. tech firm Valo Health to discover and develop new treatments for cardiometabolic diseases using human data and artificial intelligence.

Novo Nordisk and Valo to research cardiometabolic treatments

Novo Nordisk NVO, +0.01% on Monday announced a partnership with Valo Health Inc., a technology company specializing in AI-powered drug discovery and development, to focus on new cardiometabolic drug programs. The Danish pharmaceutical giant, maker of Ozempic and Wegovy, has also licensed three preclinical cardiovascular drug discovery programs from Valo, the companies said in a release.

Novo Nordisk partners with Valo Health on AI drug discovery

Collaboration will apply Valo's Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug program me s

Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence

The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.

The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.

Revenue is up 29% this year as Wegovy and Ozempic have been in high demand. Sales could go even higher as the company sorts out manufacturing issues.

Where Will Novo Nordisk Stock Be in 5 Years?

Novo Nordisk shares reached all-time highs in September but have since dropped nearly 10%. Buyers must question whether peak optimism has been priced in. With an "F" valuation grade, it isn't the time to be aggressive unless robust buying sentiments justify the market's conviction to push for higher levels. Novo Nordisk's growth could slow further through FY27, suggesting much of its medium-term upside could have been reflected.

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

An analyst reiterated his recommendation and price target. Unfortunately, that recommendation is the equivalent of a sell.

Why Novo Nordisk Stock Was Tumbling on Thursday

Novo Nordisk found "objectionable" bacteria in several batches of semaglutide, according to an FDA report. Novo Nordisk stock fell Thursday.

Novo Nordisk Stock Skids After FDA Inspection Turns Up Problematic Bacteria In Key Plant

The company inked yet another supply deal with a European healthcare tech specialist. Also, an analyst reiterated his buy recommendation on the Wegovy maker.

Why Novo Nordisk Stock Edged Higher Today

New York and Bagsværd, 20 September 2023 – Novo Nordisk and UNICEF today announced an extension of their long-term partnership to help prevent global childhood overweight and obesity - a public health crisis that affects millions of children worldwide.

Novo Nordisk and UNICEF to extend joint initiative to prevent global childhood obesity

Danish diabetes care giant Novo Nordisk is splitting its shares, with the Danish-listed B shares splitting on September 13 and the NYSE-listed ADRs splitting on September 20. This split marks a milestone in Novo Nordisk's share price appreciation, as well as making the size of options contracts more manageable to smaller investors. Novo Nordisk is one foreign stock where I prefer to trade the US ADR over the foreign local share because the US ADRs have liquid options.

Novo Nordisk: What The Stock Split Means For Traders And Investors

AbbVie

CRISPR Therapeutics

Johnson & Johnson

Molina Healthcare

Merck

Seagen

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

News for Novo Nordisk Stock (NVO)